Exploring combination treatment options for persistent methicillin-susceptible Staphylococcus aureus bacteremia

Area of Science:

• Infectious Diseases
• Pharmacology
• Clinical Medicine

Background:

• Persistent methicillin-susceptible Staphylococcus aureus bacteremia (SAB) is linked to severe outcomes, including metastatic spread, recurrence, and increased mortality.
• Effective management strategies are crucial to mitigate these risks and improve patient prognosis.

Purpose of the Study:

• To review the literature on managing persistent methicillin-susceptible Staphylococcus aureus bacteremia (SAB).
• To explore risk factors, combination treatment strategies, and stewardship implications for persistent SAB.

Main Methods:

• Literature analysis of risk factors for persistent SAB.
• Evaluation of combination therapies including daptomycin, ertapenem, ceftaroline, fosfomycin, rifampin, and gentamicin as adjuncts.
• Assessment of in vivo and clinical studies on combination therapy efficacy and safety.

Main Results:

• Combination therapies, particularly daptomycin and ertapenem, show potential benefits and synergistic effects in treating persistent SAB.
• Rifampin's biofilm penetration is noted, but mortality benefits remain inconclusive.
• Mathematical models suggest combination therapy can prevent resistance, though adverse events and costs are considerations.

Conclusions:

• Further evidence-based guidelines and studies are needed to optimize persistent SAB treatment.
• Clinical judgment is essential for tailoring treatment strategies for this challenging condition.
• Combination therapy offers a promising approach but requires careful consideration of risks and benefits.